Advances in Alzheimer's Disease
Vol.3 No.1(2014), Paper ID 43682, 10
pages
DOI:10.4236/aad.2014.31001
Options for Evaluating Treatment Benefit in MCI and Prodromal Alzheimer’s Disease: Content Validity of the Perceived Deficits Questionnaire (PDQ) in Patients with Early Symptoms of Cognitive Decline
William R. Lenderking, Anna Steenrod, Katja Rüdell, Stephanie Klapper, Kellee Howard, Maren Gaudig
Evidera, Bethesda, USA
Evidera, Bethesda, USA
Pfizer Ltd., Tadworth, UK
Evidera, Bethesda, USA
Evidera, Bethesda, USA
Health Economics & Market Access, Janssen Alzheimer Immunotherapy, Lower Grand Canal Street, Dublin, Ireland
Copyright © 2014 William R. Lenderking, Anna Steenrod, Katja Rüdell, Stephanie Klapper, Kellee Howard, Maren Gaudig et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Lenderking, W. , Steenrod, A. , Rüdell, K. , Klapper, S. , Howard, K. and Gaudig, M. (2014) Options for Evaluating Treatment Benefit in MCI and Prodromal Alzheimer’s Disease: Content Validity of the Perceived Deficits Questionnaire (PDQ) in Patients with Early Symptoms of Cognitive Decline.
Advances in Alzheimer's Disease,
3, 1-10. doi:
10.4236/aad.2014.31001.